CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin combines a GHRH analogue with a selective GHRP in a single formulation, researched for its synergistic effect on pulsatile growth hormone release and IGF-1. Published research protocols most commonly report subcutaneous administration of 100 mcg CJC-1295 + 100 mcg Ipamorelin, dosed 1–3 times daily over 8–12 week cycles. Lyophilized powder, ≥98% purity, HPLC-verified with per-batch certificate of analysis.
€159.00
In Stock
Details
CJC-1295 + Ipamorelin combines a GHRH analogue with a selective GHRP in a single formulation, researched for its synergistic effect on pulsatile growth hormone release and IGF-1. Published research protocols most commonly report subcutaneous administration of 100 mcg CJC-1295 + 100 mcg Ipamorelin, dosed 1–3 times daily over 8–12 week cycles. Lyophilized powder, ≥98% purity, HPLC-verified with per-batch certificate of analysis.
98%+ Purity
Third-party lab verified
Cold Chain
Temperature controlled
Fast Shipping
Same-day dispatch
Research Grade
For research use only
Storage
Store refrigerated at 2-8°C. Protect from light. Keep in original packaging until use.
Specifications
Format: Lyophilized powder. Purity: ≥98%. For research use only.
CJC-1295 + Ipamorelin
€159.00
Free shipping within Bulgaria on orders over €150
Same-day dispatch